Cardiovascular Journal of Africa: Vol 31 No 2 (March/April 2020)

50 / 68

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 31, No 2, March/April 2020 102 AFRICA
pressure. J Hypertens 2009; 27: 287–297.
35. Van Deventer HE, Paiker JE, Katz IJ, George JA. A comparison of
cystatin C- and creatinine-based prediction equations for the estima-
tion of glomerular filtration rate in black South Africans. Nephrol Dial
Transplant 2011; 26: 1553–1558.
36. Eastwood JB, Kerr SM, Plange-Rhule J, Micah FB, Antwi S, Boa FG,
et al. Assessment of GFR by four methods in adults in Ashanti, Ghana:
the need for an eGFR equation for lean African populations. Nephrol
Dial Transplant 2010; 25: 2178–2187.
37. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al.
The metabolic syndrome and chronic kidney disease in U.S. adults. Ann
Intern Med 2004; 140: 167–174.
38. Bamaiyi AJ, Norton GR, Norman G, Majane OHI, Sareli P, Woodwiiss
AJ. Limited contribution of insulin resistance and metabolic parameters
to obesity-associated increases in ambulatory blood pressure in a black
African community. Int J Cardiol Hypertens 2019; 2: 100010.
39. Hänninen MR, Niiranen TJ, Puukka PJ, Mattila AK, Jula AM.
Determinants of masked hypertension in the general population: the
Finn-Home study. J Hypertens 2011; 29: 1880–1888.
40. Bäckdahl J, Andersson DP, Eriksson-Hogling D, Caidahl K, Thorell
A, Mileti E, et al. Long-term improvement in aortic pulse wave velocity
after weight loss can be predicted by white adipose tissue factors. Am J
Hypertens 2018; 31: 450-457.
41. Norman G, Norton GR, Gomes M, Michel F, Majane OH, Sareli P, et al.
Circulating resistin concentrations are independently associated with aortic
pulse wave velocity in a community sample. J Hypertens 2016; 34: 274–281.
42. Menzaghi C, Salvemini L, Fini G, Thompson R, Mangiacotti D, Di
Paola R, et al. Serum resistin and kidney function: A family-based study
in non-diabetic, untreated individuals. PLoS One 2012; 7: e38414.
Trust the ! Original
S3 ISMO-20 R/7.1.4/136. Isosorbide-5-mononitrate 20 mg/tablet.
For full prescribing information, please refer to package insert.
Pharmaco Distribution (Pty) Ltd. 3 Sandown Valley Crescent, South Tower, 1st Floor, Sandton, 2196; PO Box 786522, Sandton, 2146, South Africa. Tel: + 27 11 784 0077.
Website:
1 Long-term prophylaxis and management of Angina Pectoris
2,3 = 100% bioavailability No first-pass metabolism
4 Twice daily dosage regimen shown to avoid withdrawal and tolerance
References: 1. South African approved ISMO package insert. 2. Ismo 20 Product Monograph (2015). 3. Abshagen, U., 1992. Pharmacokinetics of isosorbide mononitrate.
The American Journal of Cardiology,[online] 70(17), pp.G61-G66. 4. Thadani U, Maranda CR, Amsterdam E, et al. Lack of Pharmacological Tolerance and Rebound
Angina Pectoris during Twice-daily Therapy with Isosorbide-5-Mononitrate. Annals of Internal Medicine. 1994; 120:353-359. IS_0120.